Compare BHST & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | MCRB |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 140.7M |
| IPO Year | N/A | 2015 |
| Metric | BHST | MCRB |
|---|---|---|
| Price | $4.91 | $15.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $14.00 | ★ $14.33 |
| AVG Volume (30 Days) | 40.7K | ★ 56.4K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $32,720,000.00 | $351,000.00 |
| Revenue This Year | $116.40 | N/A |
| Revenue Next Year | $55.91 | N/A |
| P/E Ratio | ★ N/A | $25.78 |
| Revenue Growth | ★ 45.88 | N/A |
| 52 Week Low | $4.72 | $6.53 |
| 52 Week High | $12.80 | $29.98 |
| Indicator | BHST | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 44.13 |
| Support Level | $4.81 | $15.00 |
| Resistance Level | $5.45 | $16.42 |
| Average True Range (ATR) | 0.36 | 0.81 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 1.27 | 31.40 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.